Lung cancer survival trend in Umbria, Italy, 1994-2016: preliminary results

Abstract Background Lung cancer is the second most common cancer worldwide and the leading cause of death for cancer (18.4%). During the last 30 years, lung cancer incidence and mortality increased in women and decreased in men, because of tobacco smoking exposure. Population survival trend reflects both the influence of disease severity at diagnosis and treatment effectiveness. Some studies reported an increase in global lung cancer survival and linked it to new treatment options. However, change in the overall survival may also reflect a shift towards morphologies with more favorable prognosis. We analyzed overall and morphology specific survival trends for lung cancer to gain insight on the role of new treatments and changing exposures. Methods We analyzed lung cancer 1 y-survival and 3 y-survival after diagnosis in Umbria (890'000 inhabitants) in the period 1994-2016. Population-based data were obtained from the Umbrian Cancer Registry (RTUP), Italy. We estimated relative net survival (Pohar-Perme approach) stratified both for sex and histotype (NSCLC, SCLC, NOS), considering six diagnostic periods from 1994 to 2016 (4 years for period, except 3 in the last one) for 5'268 lung cancer cases (26% women). Results Overall survival by gender resulted 40,5% (1y) and 16.5% (3y) in men, 47,3% (1y) and 23,2% (3y) in women. NSCLC survival increased in women during the period 1994-2016 from 41% to 53% (1y) and from 23% to 33% (3y), and remained unchanged in men. SCLC 3 year-survival did not change significantly neither in women nor in men. Conclusions We did not observe a significant increase in lung cancer survival over a 25 years period. We observed a significant increase in survival probabilities for NSCLC among women only. Thus, our data don't confirm a major role of new treatments in improving lung cancer control. We will provide further analyses for adenocarcinoma and a comparison of incidence and mortality trends to understand the influence of exposures and treatments on survival. Key messages A general increase in lung cancer survival, as could be expected after the introduction of new highly effective treatments is not present in western countries. Reducing exposure to tobacco smoking and environmental pollution remain the main intervention to improve lung cancer control.

Download Full-text

Trends in Lung Cancer and Smoking Behavior in Italy: An Alarm Bell for Women

Tumori Journal ◽

10.5301/tj.5000684 ◽

2017 ◽

Vol 103 (6) ◽

pp. 543-550 ◽

Cited By ~ 6

Author(s):

Annalisa Trama ◽

Roberto Boffi ◽

Paolo Contiero ◽

Carlotta Buzzoni ◽

Roberta Pacifici ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Survival ◽

Smoking Behavior ◽

Cancer Control ◽

Lung Cancer Mortality ◽

Tobacco Consumption ◽

Mortality Trends ◽

Incidence And Mortality ◽

Key Driver ◽

The 1960S

Introduction The epidemiology of lung cancer is changing worldwide, with smoking being the key driver of lung cancer incidence and mortality. Our aim is to analyze the incidence, survival and mortality trends in Italy in the framework of the 2017 survey on smoking behavior in Italy. Methods AIRTUM 2017 reports on cancer survival and incidence; 2017 survey on smoking behavior in Italy. Results Men achieved progress in lung cancer control characterized by a decrease in incidence and mortality and an increase in survival. The decreasing use of tobacco in men (from 60% in the 1960s to 24% in 2017) was most likely responsible for the decreasing incidence and mortality. Women showed no progress: although survival improved slightly, the incidence and mortality were both on the rise. This was most likely due to the increasing smoking rates in women in the 1970s and 80s. Of major concern is the accelerated rise in the number of smoking women from 4.6 million in 2016 to 5.7 million in 2017 compared to the decrease observed in men (from 6.9 to 6 million). Conclusions The incidence and mortality trends in males clearly demonstrate that primary prevention is the most effective way to reduce lung cancer mortality. By contrast, a 24% increase in the prevalence of smoking among women in just 1 year is extremely worrying for the future, and calls for immediate action by targeted strategies to reduce tobacco consumption in women and avert the dreadful prospect of a lung cancer epidemic in Italy.

Download Full-text

The role of glutathione-related genes in lung cancer survival

Lung Cancer ◽

10.1016/s0169-5002(99)90721-3 ◽

1999 ◽

Vol 25 ◽

pp. S14

Author(s):

P. Yang ◽

A. Yokomizo ◽

R. Marks ◽

T. Lesnick ◽

J. Sloan ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Survival ◽

Lung Cancer Survival

Download Full-text

Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival

Journal of Thoracic Disease ◽

10.21037/jtd.2020.04.18 ◽

2020 ◽

Vol 12 (9) ◽

pp. 5086-5095

Author(s):

Idoroenyi Amanam ◽

Isa Mambetsariev ◽

Rohan Gupta ◽

Srisairam Achuthan ◽

Yingyu Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cancer Survival ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Survival

Download Full-text

Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016

Pathology & Oncology Research ◽

10.3389/pore.2021.603937 ◽

2021 ◽

Vol 27 ◽

Author(s):

Krisztina Bogos ◽

Zoltan Kiss ◽

Lilla Tamási ◽

Gyula Ostoros ◽

Veronika Müller ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Cancer Survival ◽

Survival Rates ◽

Cancer Type ◽

Lung Cancer Patients ◽

First Time ◽

Lung Cancer Survival

Objective: Lung cancer is one of the most common cancers worldwide and its survival is still poor. The objective of our study was to estimate long-term survival of Hungarian lung cancer patients at first time based on a nationwide review of the National Health Insurance Fund database.Methods: Our retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between January 1, 2011 and December 31, 2016. Survival rates were evaluated by year of diagnosis, patient gender and age, and morphology of lung cancer.Results: 41,854 newly diagnosed lung cancer patients were recorded. Mean age at diagnosis varied between 64.7 and 65.9 years during study period. One- and 5-year overall survival rates for the total population were 42.2 and 17.9%, respectively. Survival was statistically associated with gender, age and type of lung cancer. Female patients (n = 16,362) had 23% better survival (HR: 0.77, 95% confidence interval (CI): 0.75–0.79; p < 0.001) than males (n = 25,492). The highest survival rates were found in the 20–49 age cohort (5Y = 31.3%) and if the cancer type was adenocarcinoma (5Y = 20.5%). We measured 5.3% improvement (9.2% adjusted) in lung cancer survival comparing the period 2015–2016 to 2011–2012 (HR: 0.95 95% CI: 0.92–0.97; p = 0.003), the highest at females <60 year (0.86 (adjusted HR was 0.79), interaction analysis was significant for age and histology types.Conclusion: Our study provided long-term Lung cancer survival data in Hungary for the first time. We found a 5.3% improvement in 5-year survival in 4 years. Women and young patients had better survival. Survival rates were comparable to–and at the higher end of–rates registered in other East-Central European countries (7.7%–15.7%).

Download Full-text

The role of receipt and timeliness of treatment in socioeconomic inequalities in lung cancer survival: population-based, data-linkage study

Thorax ◽

10.1136/thoraxjnl-2014-205517 ◽

2014 ◽

Vol 70 (2) ◽

pp. 138-145 ◽

Cited By ~ 26

Author(s):

Lynne F Forrest ◽

Jean Adams ◽

Greg Rubin ◽

Martin White

Keyword(s):

Lung Cancer ◽

Cancer Survival ◽

Data Linkage ◽

Population Based ◽

Linkage Study ◽

Socioeconomic Inequalities ◽

Lung Cancer Survival

Download Full-text

Age disparities in lung cancer survival in New Zealand: the role of patient and clinical factors

10.1101/2020.10.05.20206912 ◽

2020 ◽

Author(s):

Sophie Pilleron ◽

Camille Maringe ◽

Hadrien Charvat ◽

June Atkinson ◽

Eva Morris ◽

...

Keyword(s):

Lung Cancer ◽

New Zealand ◽

Cancer Survival ◽

Age Difference ◽

Stage At Diagnosis ◽

Clinical Factors ◽

Emergency Presentation ◽

Age Disparities ◽

Lung Cancer Survival

AbstractBackgroundAge is an important prognostic factor for lung cancer. However, no studies have investigated the age difference in lung cancer survival per se. We, therefore, described the role of patient-related and clinical factors on the age pattern in lung cancer excess mortality hazard by stage at diagnosis in New Zealand.MethodsWe extracted 22 487 new lung cancer cases aged 50-99 (median age = 71, 47.1% females) diagnosed between 1 January 2006 and 31 July 2017 from the New Zealand population-based cancer registry and followed up to December 2019. We modelled the effect of age at diagnosis, sex, ethnicity, deprivation, comorbidity, and emergency presentation on the excess mortality hazard by stage at diagnosis, and we derived corresponding lung cancer net survival.ResultsThe age difference in net survival was particularly marked for localised and regional lung cancers, with a sharp decline in survival from the age of 70. No identified factors influenced age disparities in patients with localised cancer. However, for other stages, females had a greater age difference in survival between middle-aged and older patients with lung cancer than males. Comorbidity and emergency presentation played a minor role. Ethnicity and deprivation did not influence age disparities in lung cancer survival.ConclusionSex and stage at diagnosis were the most important factors of age disparities in lung cancer survival in New Zealand.Key messagesWhat is the key question?How do patient-related and clinical factors influence age pattern in lung cancer survival?What is the bottom line?Age disparities in lung cancer survival were strongest for females and non-advanced disease. Deprivation, ethnicity, comorbidity, and emergency presentation did not influence age disparities.Why read on?Our findings reinforce the call for a better representation of older adults in clinical trials and a wider use of geriatric assessment to identify patients who will benefit treatment.

Download Full-text